Amgen, Sanofi & Novartis Drive Multiple Myeloma Market Amid US Tariff Dynamics

The Global Multiple Myeloma Market reached USD 20.2 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 31.3 billion by 2031. The Global Multiple Myeloma Market is expected to exhibit a CAGR of 5.8% during the forecast period 2024-2031.

Multiple Myeloma Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Request a Free Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://datamintelligence.com/download-sample/multiple-myeloma-market?rk

Multiple myeloma is a cancer of plasma cells that accumulate in the bone marrow, affecting blood production. Symptoms include bone pain, anemia, and kidney dysfunction. Treatments include chemotherapy, stem cell transplant, and immunotherapy. Advances in monoclonal antibodies and CAR-T cell therapies are transforming the market. Early diagnosis and personalized medicine are improving patient outcomes.

List of the Key Players in the Multiple Myeloma Market:

Takeda Pharmaceutical Company Limited, Amgen Inc., Sanofi S.A., Novartis International AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Johnson and Johnson, Inc. (Janssen Pharmaceuticals), Bristol-Myers Squibb Company, Karyopharm Therapeutics Inc., and Ono Pharmaceutical Co., Ltd.

Industry Development:

❁ In April 2023, Bristol Myers Squibb and 2seventy bio, Inc. (Nasdaq: TSVT) announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental Biologics License Application (sBLA) for Abecma (idecabtagene vicleucel), based on the results from the KarMMa-3 study. This study explored the treatment of adults with relapsed and refractory multiple myeloma who have previously received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of December 16, 2023.

Assessing the Effects of U.S. Tariffs on the Market

The U.S. tariff war is reshaping how businesses analyze trends and make strategic decisions. As tariffs drive up costs and disrupt supply chains, companies are increasingly focused on understanding consumer behavior, identifying new sourcing opportunities, and adjusting their operations to remain competitive. The ongoing uncertainty has created a stronger demand for timely insights and data-driven strategies to navigate shifting trade dynamics and economic pressures.

Research Process:

Both primary and secondary data sources have been used in the global Multiple Myeloma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/multiple-myeloma-market?rk

Segment Covered in the Multiple Myeloma Market:

By Treatment Type: Immunotherapy, Chemotherapy, Radiation Therapy, Others

By End-user: Hospitals, Cancer Centers, Others

Regional Analysis for Multiple Myeloma Market:

The regional analysis of the Multiple Myeloma Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/multiple-myeloma-market?rk

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the Multiple Myeloma market?

➠ Who are the leading manufacturers in the global Multiple Myeloma industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global Multiple Myeloma industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the Multiple Myeloma market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Browse More Reports: https://www.datamintelligence.com/research-report/multiple-myeloma-market?rk

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.